RedHill Biopharma News and Activities

RedHill Biopharma is a company listed under the stock ticker RDHL (IL).

View the org chart displaying its 25 main executives

Most searched biographies at RedHill Biopharma

• Dror Ben-Asher, Chief Executive Officer and Chairman of the Board
• Shmuel Cabilly, Director
• Roni Mamluk, Director

Create your alert
to follow the executive moves at RedHill Biopharma.

RedHill Biopharma has 1,919 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Catalyst Pharmaceuticals, listed under ticker CPRX, has been delisted. (posted on July 13 2026).
• Angelini Pharma has acquired Catalyst Pharmaceuticals (posted on July 13 2026).
• Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals  (posted on July 7 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Richard Saynor - Chief Executive Officer at Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson

Learn more about the Pharmaceuticals industry

Press releases by RedHill Biopharma

• RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
• RedHill Biopharma Announces Up To $19.4 Million Private Placement
• RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
• RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
• RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
• RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
• RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
• RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
• Joint U.S. Commercialization of RedHill's Talicia® Commences
• RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
• View more press releases Close

Social media about RedHill Biopharma

• RedHill Biopharma on Wikipedia, Google News & Yahoo Finance
• RedHill Biopharma on LinkedIn, X (Twitter) & YouTube